To investigate the efficacy and safety of nintedanib versus placebo in Chinese patients with idiopathic pulmonary fibrosis (IPF).
The INPULSIS® trials consisted of two replicate, randomized, placebo-controlled, double-blind trials comparing nintedanib 150 mg bid with placebo over a 52-week treatment period. The primary endpoint was annual rate of decline in forced vital capacity (FVC); key secondary endpoints were change from baseline in Saint George’s Respiratory Questionnaire’s total score and time to first investigator-reported acute exacerbation. Data from both trials were pooled for the Chinese subgroup analyses.
A total of 101 Chinese patients (nintedanib/placebo: 61/40) were treated. The demographic characteristics were generally balanced between treatment arms. Over 52 weeks, the rate of decline in FVC was lower in nintedanib-treated patients compared with placebo-treated patients in the Chinese subgroup [− 126.43 vs. − 229.82 mL/year; ∆ = 103.39 mL/year (95% confidence interval, CI: − 19.40 to 226.18)]. The proportion of patients with adverse events (AEs) over 52 weeks was similar between treatment arms. The most commonly reported AEs with nintedanib treatment were gastrointestinal symptoms (diarrhoea, nausea, and vomiting).
Nintedanib is clinically efficacious in Chinese patients with IPF with approximately 50% reductions in the rate of decline in FVC, demonstrating slowed disease progression. Similar to the overall INPULSIS® population, nintedanib has a favourable benefit/risk profile in Chinese patients with IPF.
Plain Language Summary
Plain language summary available for this article.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price includes VAT (USA)
Tax calculation will be finalised during checkout.
Kreuter M, Bonella F, Wijsenbeek M, Maher TM, Spagnolo P. Pharmacological treatment of idiopathic pulmonary fibrosis: current approaches, unsolved issues, and future perspectives. Biomed Res Int. 2015;2015:329481.
Raghu G, Collard HR, Anstrom KJ, et al. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med. 2012;185(10):1044–8.
Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2018;198(5):e44–68.
Richeldi L, Cottin V, Flaherty KR, et al. Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. Respir Med. 2014;108(7):1023–30.
Olson AL, Brown KK, Swigris JJ. Understanding and optimizing health-related quality of life and physical functional capacity in idiopathic pulmonary fibrosis. Patient Relat Outcome Meas. 2016;7:29–35.
Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174(7):810–6.
Navaratnam V, Fleming KM, West J, et al. The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorax. 2011;66(6):462–7.
Lai C-C, Wang C-Y, Lu H-M, et al. Idiopathic pulmonary fibrosis in Taiwan—a population-based study. Respir Med. 2012;106(11):1566–74.
Natsuizaka M, Chiba H, Kuronuma K, et al. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med. 2014;190(7):773–9.
Dong G-H, Zhang P, Sun B, et al. Long-term exposure to ambient air pollution and respiratory disease mortality in Shenyang, China: a 12-year population-based retrospective cohort study. Respir Int Rev Thorac Dis. 2012;84(5):360–8.
Mo Z, Fu Q, Zhang L, et al. Acute effects of air pollution on respiratory disease mortalities and outpatients in Southeastern China. Sci Rep. 2018;8(1):3461.
Lee M-G, Lee YH. A meta-analysis examining the association between the MUC5B rs35705950 T/G polymorphism and susceptibility to idiopathic pulmonary fibrosis. Inflamm Res. 2015;64(6):463–70.
Xu L, Bian W, Gu X-H, Shen C. Genetic polymorphism in matrix metalloproteinase-9 and transforming growth factor-β1 and susceptibility to combined pulmonary fibrosis and emphysema in a Chinese population. Kaohsiung J Med Sci. 2017;33(3):124–9.
Hostettler KE, Zhong J, Papakonstantinou E, et al. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. Respir Res. 2014;12(15):157.
Yu Z, Wang D, Zhou Z, He S, Chen A, Wang J. Mutant soluble ectodomain of fibroblast growth factor receptor-2 IIIc attenuates bleomycin-induced pulmonary fibrosis in mice. Biol Pharm Bull. 2012;35(5):731–6.
Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015;45(5):1434–45.
Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–82.
Costabel U, Inoue Y, Richeldi L, et al. Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. Am J Respir Crit Care Med. 2016;193(2):178–85.
Corte T, Bonella F, Crestani B, et al. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respir Res. 2015;24(16):116.
Richeldi L, Kreuter M, Selman M, et al. Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension. Thorax. 2018;73(6):581–3.
Crestani B, Quaresma M, Kaye M, Stansen W, Stowasser S, Kreuter M. Long-term nintedanib treatment in idiopathic pulmonary fibrosis (IPF): new data from INPULSIS-ON. Eur Respir J. 2017;50(Supp 61):OA3402.
Taniguchi H, Xu Z, Azuma A, et al. Subgroup analysis of Asian patients in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis. Respirology. 2016;21(8):1425–30.
Azuma A, Taniguchi H, Inoue Y, et al. Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: a subgroup analysis of the INPULSIS® randomized trials. Respirol Carlton Vic. 2017;22(4):750–7.
Collard HR, Yow E, Richeldi L, Anstrom KJ, Glazer C, IPFnet investigators. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res. 2013;14:73.
Rogliani P, Calzetta L, Cavalli F, Matera MG, Cazzola M. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Pulm Pharmacol Ther. 2016;40:95–103.
Jones PW, Quirk FH, Baveystock CM. The St George’s respiratory questionnaire. Respir Med. 1991;85(Suppl B):25–31.
Richeldi L, Cottin V, du Bois RM, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS(®) trials. Respir Med. 2016;113:74–9.
Huang H, Peng X, Zhong C. Idiopathic pulmonary fibrosis: the current status of its epidemiology, diagnosis, and treatment in China. Intractable Rare Dis Res. 2013;2(3):88–93.
Swigris JJ, Esser D, Conoscenti CS, Brown KK. The psychometric properties of the St George’s Respiratory Questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature review. Health Qual Life Outcomes. 2014;20(12):124.
Jankowich MD, Rounds SIS. Combined pulmonary fibrosis and emphysema syndrome: a review. Chest. 2012;141(1):222–31.
Rodríguez-Portal JA. Efficacy and safety of nintedanib for the treatment of idiopathic pulmonary fibrosis: an update. Drugs RD. 2018;18(1):19–25.
Wang F-S, Fan J-G, Zhang Z, Gao B, Wang H-Y. The global burden of liver disease: the major impact of China. Hepatol Baltim Md. 2014;60(6):2099–108.
The authors would like to thank Zhancheng Gao, Peking University People’s Hospital, Beijing; Zhikui Li, Xijing Hospital, 4th Military Medical University, Xi’an; Huanying Wan, Shanghai Ruijin Hospital, Shanghai; Haoyan Wang, Beijing Friendship Hospital, Beijing; Qiming Xiao, Xiangya Hospital, Central South University, Changsha; Wei Zhang, The First Affiliated Hospital of Nanchang University, Nanchang; Xiwei Zheng, General Hospital of Ningxia Medical University, Yinchuan; Huili Zhu, Shanghai Huadong Hospital, Shanghai for their efforts during the trials in China. The authors also thank the participants of the study.
The INPULSIS® trials were funded by Boehringer Ingelheim. The article processing charges were funded by Boehringer Ingelheim.
Medical Writing and/or Editorial Assistance
Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Hui Chin Teoh during the development of this article.
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. Jian Kang is the guarantor of this work and, had full access to all the data in the study, and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis.
Zuojun Xu acted as a principal investigator of the INPULSIS® trials in China, and received investigator fees for the roles. Huiping Li acted as a principal investigator of the INPULSIS® trials in China, and received investigator fees for the roles. Fuqiang Wen acted as a principal investigator of the INPULSIS® trials in China, and received investigator fees for the roles. Chunxue Bai acted as a principal investigator of the INPULSIS® trials in China, and received investigator fees for the roles. Ping Chen acted as a principal investigator of the INPULSIS® trials in China, and received investigator fees for the roles. Jian Kang acted as a principal investigator of the INPULSIS® trials in China, and received investigator fees for the roles. Feng Fan is an employee of Boehringer Ingelheim. Na Hu is an employee of Boehringer Ingelheim. Susanne Stowasser is an employee of Boehringer Ingelheim. None of the listed authors received any payment for their participation in the writing of this manuscript.
Compliance with Ethics Guidelines
This post hoc subgroup analysis is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors. The main INPULSIS® trials were conducted in accordance with the principles of the Declaration of Helsinki and the Harmonized Tripartite Guideline for Good Clinical Practice from the International Conference on Harmonization and were approved by local authorities. The clinical protocol was approved by an independent ethics committee or institutional review board at each participating centre. All patients provided written informed consent before study entry.
The datasets generated for this study can be accessed and analysed via application to the Clinical Study Data Request (CSDR) website at https://www.clinicalstudydatarequest.com.
Enhanced digital features
To view enhanced digital features for this article go to https://doi.org/10.6084/m9.figshare.7604903.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Xu, Z., Li, H., Wen, F. et al. Subgroup Analysis for Chinese Patients Included in the INPULSIS® Trials on Nintedanib in Idiopathic Pulmonary Fibrosis. Adv Ther 36, 621–631 (2019). https://doi.org/10.1007/s12325-019-0887-1
- Forced vital capacity
- Idiopathic pulmonary fibrosis
- Randomized controlled trial